Iron in Chronic Brain Disorders: Imaging and Neurotherapeutic Implications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Pujol, 1992, Biological significance of iron-related magnetic resonance imaging changes in the brain, Arch Neurol, 49, 711, 10.1001/archneur.1992.00530310053012
Wills, 2002, Palatal tremor and cognitive decline in neuroferritinopathy, J Neurol Neurosurg Psychiatry, 73, 91, 10.1136/jnnp.73.1.91
Riederer, 1989, Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains, J Neurochem, 52, 515, 10.1111/j.1471-4159.1989.tb09150.x
Dexter, 1987, Increased nigral iron content in post-mortem parkinsonian brain, Lancet, 341, 1219, 10.1016/S0140-6736(87)91361-4
Jenner, 1991, Oxidative stress as a cause of Parkinson’s disease, Acta Neurol Scand Suppl, 136, 6, 10.1111/j.1600-0404.1991.tb05013.x
Jenner, 1996, Oxidative stress and the pathogenesis of Parkinson’s disease, Neurology, 47, S161
Cohen, 2000, Oxidative stress, mitochondrial respiration, and Parkinson’s disease, Ann NY Acad Sci, 899, 112, 10.1111/j.1749-6632.2000.tb06180.x
Youdim, 1993, Parkinson’s disease and increased iron levels in substantia nigra zona compacta, Mov Disord, 8, 1, 10.1002/mds.870080102
House, 2007, Correlation of proton transverse relaxation rates (R2) with iron concentrations in postmortem brain tissue from Alzheimer’s disease patients, Magn Reson Med, 57, 172, 10.1002/mrm.21118
Loeffler, 1995, Transferrin and iron in normal, Alzheimer’s disease, and Parkinson’s disease brain regions, J Neurochem, 65, 710, 10.1046/j.1471-4159.1995.65020710.x
Connor, 1992, Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease, J Neurosci Res, 31, 327, 10.1002/jnr.490310214
Cornett, 1998, Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain, Neurotoxicology, 19, 339
Dedman, 1992, Iron and aluminum in relation to brain ferritin in normal individuals and Alzheimer’s-disease and chronic renal-dialysis patients, Biochem J, 287, 509, 10.1042/bj2870509
Ehmann, 1986, Brain trace elements in Alzheimer’s disease, Neurotoxicology, 7, 195
Honda, 2004, Oxidative stress and redox-active iron in Alzheimer’s disease, Ann NY Acad Sci, 1012, 179, 10.1196/annals.1306.015
Drayer, 1987, Reduced signal intensity on MR Images of thalamus and putamen in multiple sclerosis: increased iron content?, AJR Am J Roentgenol, 149, 357, 10.2214/ajr.149.2.357
Bakshi, 2002, T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study, Arch Neurol, 59, 62, 10.1001/archneur.59.1.62
Craelius, 1982, Iron deposits surrounding multiple sclerosis plaques, Arch Pathol Lab Med, 106, 397
Inglese, 2005, Iron accumulation in the deep gray matter of patients with MS measured by magnetic field correlation, Neurology, 64, A236
Brass, 2006, Magnetic resonance imaging of iron deposition in neurological disorders, Top Magn Reson Imaging, 17, 31, 10.1097/01.rmr.0000245459.82782.e4
Ritchie, 2003, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial, Arch Neurol, 60, 1685, 10.1001/archneur.60.12.1685
Crapper McLachlan, 1991, Intramuscular desferrioxamine in patients with Alzheimer’s disease, Lancet, 337, 1304, 10.1016/0140-6736(91)92978-B
Lynch, 2000, A multiple course trial of desferrioxamine in chronic progressive multiple sclerosis, Cell Mol Biol, 46, 865
Schenck, 2003, Magnetic resonance imaging of brain iron, J Neurol Sci, 207, 99, 10.1016/S0022-510X(02)00431-8
Haacke, 2005, Imaging iron stores in the brain using magnetic resonance imaging, Magn Reson Imaging, 23, 1, 10.1016/j.mri.2004.10.001
Vymazal, 1996, The relation between brain iron and NMR relaxation times: an in vitro study, Magn Reson Med, 35, 56, 10.1002/mrm.1910350108
Chen, 1989, T2 values in the human brain: comparison with quantitative assays of iron and ferritin, Radiology, 173, 521, 10.1148/radiology.173.2.2798884
Bartzokis, 1994, In vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI, Biol Psych, 35, 480, 10.1016/0006-3223(94)90047-7
Bartzokis, 1999, MRI evaluation of brain iron in earlier- and later-onset Parkinson’s disease and normal subjects, Magn Reson Imaging, 17, 213, 10.1016/S0730-725X(98)00155-6
Bartzokis, 2000, MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntington’s disease, Cell Mol Biol, 46, 821
Gelman, 1999, MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content, Radiology, 210, 759, 10.1148/radiology.210.3.r99fe41759
Metafratzi, 2001, T(2) relaxation rate of basal ganglia and cortex in patients with beta-thalassaemia major, Br J Radiol, 74, 407, 10.1259/bjr.74.881.740407
Schenck, 1995, Imaging of brain iron by magnetic resonance: T2 relaxation at different field strengths, J Neurol Sci, 134, 10, 10.1016/0022-510X(95)00203-E
Vymazal, 1999, T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content, Radiology, 211, 489, 10.1148/radiology.211.2.r99ma53489
Hardy, 2005, Correlation of R2 with total iron concentration in the brains of rhesus monkeys, J Magn Reson Imaging, 21, 118, 10.1002/jmri.20244
Graham, 2000, Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence, Brain, 123, 2423, 10.1093/brain/123.12.2423
Whittall, 1997, In vivo measurement of T2 distributions and water contents in normal human brain, Magn Reson Med, 37, 34, 10.1002/mrm.1910370107
Ordidge, 1994, Assessment of relative brain iron concentrations using T2-weighted and T2*-weighted MRI at 3 Tesla, Magn Reson Med, 32, 335, 10.1002/mrm.1910320309
Gorell, 1995, Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease, Neurology, 45, 1138, 10.1212/WNL.45.6.1138
Antonini, 1993, T2 relaxation time in patients with Parkinson disease, Neurology, 43, 697, 10.1212/WNL.43.4.697
Bartzokis, 1993, Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores, Magn Reson Med, 29, 459, 10.1002/mrm.1910290406
Reichenbach, 1997, Theory and application of static field inhomogeneity effects in gradient-echo imaging, J Magn Reson Imaging, 7, 266, 10.1002/jmri.1880070203
Ma, 1996, Method for image-based measurement of the reversible and irreversible contribution to the transverse-relaxation rate, J Magn Reson Imaging, 111, 61
Song, 2007, Echo-spacing optimization for the simultaneous measurement of reversible (R2’) and irreversible (R2) transverse relaxation rates, Magn Reson Imaging, 25, 63, 10.1016/j.mri.2006.09.008
Hikita, 2005, Determination of transverse relaxation rate for estimating iron deposits in central nervous system, Neurosci Res, 51, 67, 10.1016/j.neures.2004.09.006
Yablonskiy, 1997, An MRI method for measuring T2 in the presence of static and RF magnetic field inhomogeneities, Magn Reson Med, 37, 872, 10.1002/mrm.1910370611
Wheaton, 2004, T2rho-weighted contrast in MR images of the human brain, Magn Reson Med, 52, 1223, 10.1002/mrm.20284
Michaeli, 2007, Assessment of brain iron and neuronal integrity in patients with Parkinson’s disease using novel MRI contrasts, Mov Disord, 22, 334, 10.1002/mds.21227
Ponka, 2004, Heredity causes of disturbed iron homeostasis in the central nervous system, Ann NY Acad Sci, 1012, 267, 10.1196/annals.1306.022
Connor, 1996, Relationship of iron to oligodendrocytes and myelination, Glia, 17, 83, 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7
Floris, 2000, The physiopathological significance of ceruloplasmin, Biochem Pharmacol, 60, 1735, 10.1016/S0006-2952(00)00399-3
Pantopoulos, 2004, Iron metabolism and the IRE/IRP regulator system: an update, Ann NY Acad Sci, 1012
Ke, 2003, Iron misregulation in the brain: a primary cause of neurodegenerative disorders, Lancet Neurol, 2, 246, 10.1016/S1474-4422(03)00353-3
Connor, 1994, Isoforms of ferritin have a specific cellular distribution in the brain, J Neurosci Res, 37, 461, 10.1002/jnr.490370405
Levi, 1992, Evidence that H- and L-chains have co-operative roles in the iron-uptake mechanism of human ferritin, J Biochem, 288, 591, 10.1042/bj2880591
Zecca, 2004, The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging, Proc Natl Acad Sci U S A, 101, 9843, 10.1073/pnas.0403495101
Zecca, 2006, A proposed dual role of neuromelanin in the pathogenesis of Parkinson’s disease, Neurology, 67, S8
Moos, 1998, Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid, J Neurosci Res, 54, 486, 10.1002/(SICI)1097-4547(19981115)54:4<486::AID-JNR6>3.0.CO;2-I
Curtis, 2001, Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease, Nat Genet, 28, 350, 10.1038/ng571
Schipper, 2004, Heme oxygemase-1: transducer of pathological brain iron sequestration under oxidative stress, Ann NY Acad Sci, 1012, 84, 10.1196/annals.1306.007
Fenton, 1894, Oxidation of tartaric acid in presence of iron, J Chem Soc, 65, 899, 10.1039/CT8946500899
Liddell, 2006, Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity, J Neurosci Res, 84, 578, 10.1002/jnr.20957
Aguirre, 2006, Antioxidant responses of cortex neurons to iron loading, Biol Res, 39, 103, 10.4067/S0716-97602006000100012
Crichton, 2002, Molecular and cellular mechanisms of iron homeostasis and toxicity in mammalian cells, J Inorg Biochem, 91, 9, 10.1016/S0162-0134(02)00461-0
Van der Worp, 1999, Inhibition of iron-dependent and ischemia-induced brain damage by the alpha-tocopherol analogue MDL74,722, Exp Neurol, 155, 103, 10.1006/exnr.1998.6968
de Jesus Ferreira, 2005, A transient treatment of hippocampal neurons with alpha-tocopherol induces a long-lasting protection against oxidative damage via a genomic action, Free Radic Biol Med, 39, 1009, 10.1016/j.freeradbiomed.2005.05.021
Moos, 2002, Brain iron homeostasis, Dan Med Bull, 49, 279
Connor, 1990, Cellular distribution of transferrin, ferritin and iron in normal and aged human brains, J Neurosci Res, 27, 595, 10.1002/jnr.490270421
Zucca, 2006, Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability, J Neural Transm, 113, 757, 10.1007/s00702-006-0453-2
Zecca, 2004, Iron, brain ageing and neurodegenerative disorders, Nat Rev Neurosci, 5, 863, 10.1038/nrn1537
Hallgren, 1958, The effect of age on the non-haemin iron in the human brain, J Neurochem, 3, 41, 10.1111/j.1471-4159.1958.tb12607.x
Thomas, 1993, MR detection of brain iron, AJNR Am J Neuroradiol, 14, 1043
Milton, 1991, Deep gray matter hypointensity patterns with aging in healthy adults: MR imaging at 1.5T, Radiology, 181, 715, 10.1148/radiology.181.3.1947087
Bartzokis, 1997, MR evaluation of age-related increase of brain iron in young adult and older normal males, Magn Reson Imaging, 15, 29, 10.1016/S0730-725X(96)00234-2
Bartzokis, 2007, Brain ferritin iron may influence age- and gender-related risks of neurodegeneration, Neurobiol Aging, 28, 414, 10.1016/j.neurobiolaging.2006.02.005
Cass, 2007, Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys, Neurobiol Aging, 28, 258, 10.1016/j.neurobiolaging.2005.12.010
Richardson, 2004, Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions, Ann NY Acad Sci, 1012, 326, 10.1196/annals.1306.026
Rottkamp, 2001, Redox-active iron mediates amyloid-β toxicity, Free Radical Biol Med, 30, 447, 10.1016/S0891-5849(00)00494-9
Mantyh, 1993, Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide, J Neurochem, 61, 1171, 10.1111/j.1471-4159.1993.tb03639.x
Bishop, 2000, β-Amyloid helps to protect neurons from oxidative stress, Neurobiol Aging, 21, 226, 10.1016/S0197-4580(00)83347-3
Van Landeghem, 1998, Transferrin C2, metal binding and Alzheimer’s disease, Neuroreport, 9, 177, 10.1097/00001756-199801260-00001
Pulliam, 2003, Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer’s disease and correlation with APOE, Am J Med Genet B Neuropsychiatr Genet, 119, 48, 10.1002/ajmg.b.10069
Bartzokis, 2000, In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging, Arch Gen Psychiatry, 57, 47, 10.1001/archpsyc.57.1.47
Bartzokis, 2004, Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases, Ann NY Acad Sci, 1012, 224, 10.1196/annals.1306.019
House, 2006, Quantitative MR imaging R2 relaxometry in elderly participants reporting memory loss, AJNR Am J Neuroradiol, 27, 430
Cherny, 2001, Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer’s disease transgenic mice, Neuron, 30, 665, 10.1016/S0896-6273(01)00317-8
Uitti, 1989, Regional metal concentrations in Parkinson’s disease, other chronic neurological diseases, and control brains, Can J Neurol Sci, 16, 310, 10.1017/S0317167100029140
Galazka-Friedman, 1996, Iron in parkinsonian and control substantia nigra: a Mossbauer spectroscopy study, Mov Disord, 11, 8, 10.1002/mds.870110104
Youdim, 1989, Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration, Acta Neurol Scand, 126, 47, 10.1111/j.1600-0404.1989.tb01782.x
Levenson, 2003, Iron and Parkinson’s disease: Chelators to the rescue?, Nutr Rev, 61, 311, 10.1301/nr.2003.sept.311-313
Andersen, 2001, Do alterations in glutathione and iron levels contribute to pathology associated with Parkinson’s disease?, Novartis Found Symp, 235, 11, 10.1002/0470868694.ch3
Dexter, 1990, Decreased ferritin levels in brain in Parkinson’s disease, J Neurochem, 55, 16, 10.1111/j.1471-4159.1990.tb08814.x
Zecca, 2005, In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage, Mov Disord, 20, 1278, 10.1002/mds.20550
Atasoy, 2004, T2-weighted MRI in Parkinson’s disease; substantia nigra pars compacta hypointensity correlates with the clinical scores, Neurology India, 52, 332
Kosta, 2006, MRI evaluation of the basal ganglia size and iron content in patients with Parkinson’s disease, J Neurol, 253, 26, 10.1007/s00415-005-0914-9
Gerlach, 2006, Potential sources of increased iron in the substantia nigra of parkinsonian patients, J Neural Transm Suppl, 70, 133
Shoham, 2004, Nutritional iron deprivation attenuates kainate-induced neurotoxicity in rats: implications for involvement of iron in neurodegeneration, Ann NY Acad Sci, 1012, 94, 10.1196/annals.1306.008
Ben-Shachar, 1991, The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons, J Neurochem, 56, 1441, 10.1111/j.1471-4159.1991.tb11444.x
Lan, 1997, Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice, J Neural Transm, 104, 469, 10.1007/BF01277665
Kaur, 2003, Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease, Neuron, 27, 899, 10.1016/S0896-6273(03)00126-0
Bakshi, 2000, MRI T2 shortening (“black T2”) in multiple sclerosis: frequency, location, and clinical correlation, Neuroreport, 11, 15, 10.1097/00001756-200001170-00004
Tjoa, 2005, MRI T2 hypointensity of the dentate nucleus is related to ambulatory impairment in multiple sclerosis, J Neurol Sci, 234, 17, 10.1016/j.jns.2005.02.009
Neema, 2007, T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis, J Neuroimaging, 17, 16
LeVine, 1997, Iron deposits in multiple sclerosis and Alzheimer’s disease brains, Brain Res, 760, 298, 10.1016/S0006-8993(97)00470-8
Mehindate, 2001, Proinflammatory cytokines promote glial heme oxygenase-1 expression and mitochondrial iron deposition: implications for multiple sclerosis, J Neurochem, 77, 1386, 10.1046/j.1471-4159.2001.00354.x
Chakrabarty, 2003, Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis, Multiple Sclerosis, 9, 372, 10.1191/1352458503ms928oa
Forge, 1998, Iron deposits in the central nervous system of SJL mice with experimental allergic encephalomyelitis, Life Sci, 63, 2271, 10.1016/S0024-3205(98)00512-8
Bakshi, 2000, MRI T2 shortening (“black T2”) in multiple sclerosis: frequency, location, and clinical correlation, Neuroreport, 11, 15, 10.1097/00001756-200001170-00004
Brass, 2006, Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis, Mult Scler, 12, 437, 10.1191/135248506ms1301oa
Bermel, 2005, Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity, Arch Neurol, 62, 1371, 10.1001/archneur.62.9.1371
Zhang, 2007, Deep gray matter “black T2” on 3 tesla magnetic resonance image correlates with disability in multiple sclerosis, Mult Scler, 10.1177/1352458507076411
Bowern, 1984, Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent, J Exp Med, 160, 1532, 10.1084/jem.160.5.1532
Willenborg, 1988, Inhibition of allergic encephalomyelitis by the iron chelating agent desferrioxamine: differential effect depending on type of sensitizing encephalitogen, J Neuroimmunol, 17, 127, 10.1016/0165-5728(88)90020-3
Pedchenko, 1998, Desferrioxamine suppresses experimental allergic encephalomyelitis induced by MBP in SJL mice, J Neuroimmunol, 84, 188, 10.1016/S0165-5728(97)00256-7
Weilbach, 2004, The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis, Clin Exp Immunol, 135, 49, 10.1111/j.1365-2249.2004.02344.x
Pai, 2000, Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention, Drug Saf, 4, 263, 10.2165/00002018-200022040-00002
Mancuso, 2005, Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights, J Neuropathol Exp Neurol, 64, 280, 10.1093/jnen/64.4.280
Chinnery, 2007, Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation, Brain, 130, 110, 10.1093/brain/awl319
Duby, 2002, A non-essential function for yeast frataxin in iron-sulfur cluster assembly, Hum Mol Genet, 11, 2635, 10.1093/hmg/11.21.2635
Waldvogel, 1999, Increased iron in the dentate nucleus of patients with Friedrich’s ataxia, Ann Neurol, 46, 123, 10.1002/1531-8249(199907)46:1<123::AID-ANA19>3.0.CO;2-H
Hart, 2005, Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up, Arch Neurol, 62, 621, 10.1001/archneur.62.4.621
Hayflick, 2006, Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations, AJNR Am J Neuroradiol, 27, 1230
Zhou, 2001, A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome, Nat Genet, 28, 345, 10.1038/ng572
Hayflick, 2003, Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name, Curr Opin Pediatr, 15, 572, 10.1097/00008480-200312000-00005
Xu, 2004, Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis, Ann N Y Acad Sci, 1012, 299, 10.1196/annals.1306.024
Kawanami, 1996, Hereditary caeruloplasmin deficiency: clinicopathological study of a patient, J Neurol Neurosurg Psychiatry, 61, 506, 10.1136/jnnp.61.5.506
Grisoli, 2005, MR imaging of cerebral cortical involvement in aceruloplasminemia, AJNR Am J Neuroradiol, 26, 657
Harris, 1999, Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux, Proc Natl Acad Sci USA, 96, 10812, 10.1073/pnas.96.19.10812
Vassiliev, 2005, Ceruloplasmin in neurodegenerative diseases, Brain Res Brain Res Rev, 49, 633, 10.1016/j.brainresrev.2005.03.003
Miyajima, 1997, Use of desferrioxamine in the treatment of aceruloplasminemia, Ann Neurol, 41, 404, 10.1002/ana.410410318
Loreal, 2002, Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights, J Hepatol, 36, 851, 10.1016/S0168-8278(02)00042-9
Kuhn, 2007, Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate, Brain Dev, 7, 450, 10.1016/j.braindev.2007.01.001
Levy, 2007, Superficial siderosis: a case report and review of the literature, Nat Clin Pract Neurol, 3, 54, 10.1038/ncpneuro0356
Koeppen, 1993, The pathogenesis of superficial siderosis of the central nervous system, Ann Neurol, 34, 646, 10.1002/ana.410340505
Unger, 1994, Toluene abuse: physical basis for hypointensity of the basal ganglia on T2-weighted images, Radiology, 193, 473, 10.1148/radiology.193.2.7972765
Kamran, 1998, MRI in chronic toluene abuse: low signal in the cerebral cortex on T2-weighted images, Neuroradiology, 40, 519, 10.1007/s002340050637
Nielsen, 1995, Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome, J Neurol Neurosurg Psychiatry, 59, 318, 10.1136/jnnp.59.3.318
Savoiardo, 2003, Differential diagnosis of Parkinson’s disease and atypical parkinsonian disorder by magnetic resonance imaging, Neurol Sci, 24, S35, 10.1007/s100720300036
Hauser, 1996, Magnetic resonance imaging of corticobasal degeneration, J Neuroimaging, 6, 222, 10.1111/jon199664222
Dietrich, 1988, Iron accumulation in the basal ganglia following severe ischemic-anoxic insults in children, Radiology, 168, 203, 10.1148/radiology.168.1.3380958
Hall, 1992, Novel inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders, Ann Neurol, 32, S137, 10.1002/ana.410320724
Feng, 2000, Desmethyl tirilazad improves neurologic function after hypoxic-ischemic brain injury in piglets, Crit Care Med, 28, 1431, 10.1097/00003246-200005000-00029
Soloniuk, 1992, Use of allopurinol and deferoxamine in cellular protection during ischemia, Surg Neurol, 38, 110, 10.1016/0090-3019(92)90087-4
Rosenthal, 1992, Prevention of post-ischemic brain lipid conjugated diene production and neurological injury by hydroxyethyl starch-conjugated deferoxamine, Free Radic Biol Med, 12, 29, 10.1016/0891-5849(92)90055-L
1996, A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS), Stroke, 27, 1453, 10.1161/01.STR.27.9.1453
Haley, 1998, High-dose tirilazad for acute stroke (RANTTAS II), Stroke, 29, 1256, 10.1161/str.29.6.1256/a
Balla, 1991, Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species, Lab Invest, 64, 648
Long, 1996, Deferoxamine improves spatial memory performance following experimental brain injury in rats, Brain Res, 717, 109, 10.1016/0006-8993(95)01500-0
Panter, 1992, Dextran-coupled deferoxamine improves outcome in a murine model of head injury, J Neurotrauma, 9, 47, 10.1089/neu.1992.9.47
Marshall, 1998, A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury, J Neurosurg, 89, 519, 10.3171/jns.1998.89.4.0519
Qian, 2000, Glycochelates and the etiology of diabetic peripheral neuropathy, Free Radic Biol Med, 28, 652, 10.1016/S0891-5849(99)00262-2
Cameron, 1995, Neurovascular dysfunction in diabetic rats, J Clin Invest, 96, 1159, 10.1172/JCI118104
Cameron, 2001, Effects of an extracellular metal chelator on neurovascular function in diabetic rats, Diabetologia, 44, 621, 10.1007/s001250051669
Fernandez-Real, 2002, Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity, Diabetes Care, 25, 2249, 10.2337/diacare.25.12.2249
Duffy, 2001, Iron chelation improves endothelial function in patients with coronary artery disease, Circulation, 103, 2799, 10.1161/01.CIR.103.23.2799
Buyse, 2003, Idebenone treatment in Friedreich’s ataxia, Neurology, 60, 1679, 10.1212/01.WNL.0000068549.52812.0F
Pratico, 2001, Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis, J Neurosci, 21, 4183, 10.1523/JNEUROSCI.21-12-04183.2001
Petersen, 2005, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med, 352, 2379, 10.1056/NEJMoa050151
Sano, 1997, A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease, N Engl J Med, 336, 1216, 10.1056/NEJM199704243361704
Levites, 2001, Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration, J Neurochem, 78, 1073, 10.1046/j.1471-4159.2001.00490.x
Fahn, 1992, The oxidant stress hypothesis in idiopathic Parkinson’s: evidence supporting it, Ann Neurol, 32, 799, 10.1002/ana.410320616
Singh, 2007, Advances in the treatment of Parkinson’s disease, Prog Neurobiol, 81, 29, 10.1016/j.pneurobio.2006.11.009
Lehmann, 1994, Oral administration of the oxidant scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis, J Neuroimmunol, 50, 35, 10.1016/0165-5728(94)90212-7
Ruuls, 1995, Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats, J Neuroimmunol, 56, 207, 10.1016/0165-5728(94)00154-G
Hansen, 1995, Suppression of hyperacute and passively transferred experimental autoimmune encephalomyelitis by the antioxidant, butylated hydroxyanisole, J Neuroimmunol, 62, 69, 10.1016/0165-5728(95)00104-A
Malfroy, 1997, Prevention and suppression of autoimmune encephalomyelitis by EUK-8, a synthetic catalytic scavenger of oxygen-reactive metabolites, Cell Immunol, 177, 62, 10.1006/cimm.1997.1091
Marracci, 2002, Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis, J Neuroimmunol, 13, 104, 10.1016/S0165-5728(02)00269-2
Aktas, 2004, Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis, J Immunol, 173, 5794, 10.4049/jimmunol.173.9.5794
Bjelakovic, 2007, Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis, JAMA, 297, 842, 10.1001/jama.297.8.842
Lee, 2004, The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human b-amyloid precursor protein transgenic mice, Neurobiol Aging, 25, 1315, 10.1016/j.neurobiolaging.2004.01.005
Shin, 2003, A novel trivalent cation chelator Feralex dissociates binding of aluminum and iron associated with hyperphosphorylated tau of Alzheimer’s disease, Brain Res, 961, 139, 10.1016/S0006-8993(02)03893-3
Gaeta, 2005, The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy, Br J Pharmacol, 146, 1041, 10.1038/sj.bjp.0706416
Ben-Shachar, 2004, Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats, Neuropharmacology, 46, 254, 10.1016/j.neuropharm.2003.09.005
Gal, 2005, Novel multifunctional neuroprotective iron chelator–monoamine oxidase inhibitor drugs for neurodegenerative diseases, J Neurochem, 95, 79, 10.1111/j.1471-4159.2005.03341.x